Soleno Therapeutics (BST:6XC1) - Cotización, noticias y análisis

Resumen de acción 6XC1

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Acerca de la empresa

6XC1 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Los accionistas han sido diluidos sustancialmente en el último año

Acciones altamente ilíquidas

No tiene una capitalización de mercado significativa (€23M)

+ 1 riesgos adicionales

Competidores de Soleno Therapeutics, Inc.

Medigene

XTRA:MDG1

€37.2m

2invest

XTRA:2INV

€48.9m

co.don

XTRA:CNW

€6.5m

4SC

DB:VSC

€85.0m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Soleno Therapeutics
Historical stock prices
Current Share Price	US$0.17
52 Week High	US$0.77
52 Week Low	US$0.16
Beta	0.24
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-77.36%
3 Year Change	n/a
5 Year Change	-88.30%
Change since IPO	-99.33%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	6XC1	DE Biotechs	Mercado DE
7D	0%	-1.5%	1.9%
1Y	-77.4%	-23.6%	4.6%

Rentabilidad vs. Industria: 6XC1 obtuvo unos resultados inferiores a los del sector German Biotechs , que el año pasado arrojó un rendimiento del -21.1%.

Rentabilidad vs. Mercado: 6XC1 obtuvo unos resultados inferiores a los del mercado German, que fue del -0.3% el año pasado.

Volatilidad de los precios

Is 6XC1's price volatile compared to industry and market?
6XC1 volatility
6XC1 Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.4%

Precio estable de las acciones: 6XC1 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de 6XC1 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1999	20	Anish Bhatnagar	soleno.life

Resumen de fundamentos de Soleno Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Soleno Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de 6XC1
Capitalización bursátil	€22.99m
Beneficios(TTM)	-€23.01m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-1.0x

Ratio precio-beneficio (PE)

¿Está 6XC1 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 6XC1
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$23.42m
Beneficios	-US$23.42m

Últimos beneficios comunicados

Jun 30, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.19
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 6XC1 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 6XC1

Recompensas

Análisis de riesgos

Competidores de Soleno Therapeutics, Inc.

XTRA:MDG1

€37.2m

XTRA:2INV

€48.9m

XTRA:CNW

€6.5m

DB:VSC

€85.0m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

Recent updates

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

New 90-day low: €1.14

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: €1.85

New 90-day high: €1.70

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

New 90-day low: €1.35

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Soleno Therapeutics, Inc.

0.0x

-1.0x

Beneficios e Ingresos